Locust Walk

Locust Walk Locust Walk is a global life science transaction firm. WE BELIEVE THAT NO TWO PATHS ARE THE SAME.

Our team fuels the growth of promising biopharma companies at every stage, by connecting the right products, the right partners, and the most attractive sources of capital – driving innovation for growth and transformative results. Locust Walk operates on one powerful guiding principle: that our role is to craft and execute customized partnering and financing strategies designed to meet the specif

ic desires, needs, and goals of every company and each investor. We launch each relationship without preconceived opinions or goals. Our mission is to identify and facilitate an efficient, rapid, and unique growth trajectory for every company. However, our work is firmly rooted in best practices that inform all of our transactions. Locust Walk has closed high value transactions for multiple clients across a variety of therapeutic areas and modalities. The breadth of our success includes sell-side, buy-side and financing deals. Examples of recent client engagements where Locust Walk served as a transaction advisor are listed on our website. We would encourage you to click on each case study and/or press release to learn about each assignment in greater detail.

01/02/2020

Congratulations to the Xyphos Biosciences team for their acquisition by Astellas. They found a great partner to help them develop next generation cell therapies and we are very proud to have worked with such a great team. Click here to read the press release:

On Thursdays our Analysts match.
12/12/2019

On Thursdays our Analysts match.

Lubor Gaal, SVP, Head of Europe at Locust Walk, sat down with EBD Group in preparation for his panel at  .
11/11/2019

Lubor Gaal, SVP, Head of Europe at Locust Walk, sat down with EBD Group in preparation for his panel at .

Join Lubor Gaal of Locust Walk and his esteemed panelists at BIO-Europe November 12 from 10-11 am to discuss non-binding...
11/06/2019

Join Lubor Gaal of Locust Walk and his esteemed panelists at BIO-Europe November 12 from 10-11 am to discuss non-binding term sheets.

We want you to master one of the most important elements in a successful transaction process--the handling of the term s...
10/23/2019

We want you to master one of the most important elements in a successful transaction process--the handling of the term sheet! Lubor Gaal's recent article in the September issue of BiopharmaDealmakers, "Biopharma Dealmaking: Negotiating Your Term Sheet," is available now. Click below to read (pages 13-14)
https://biopharmadealmakers.nature.com/pages/npg-latest-edition-bpdm

Locust Walk's medtech team has compiled key statistics and trends on strategic transactions and financings, with a focus...
10/11/2019

Locust Walk's medtech team has compiled key statistics and trends on strategic transactions and financings, with a focus on upcoming trends. Click below to download: http://bit.ly/Q3MedtechReport

Q3 2019 Report: Global Trends in Medtech Transactions Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get t...

At the end of each quarter, our biopharma team here at Locust Walk reviews the global trends in biopharma transactions w...
10/10/2019

At the end of each quarter, our biopharma team here at Locust Walk reviews the global trends in biopharma transactions with an eye on future trends. Click below to download.
http://bit.ly/Q3BioReport

Based on recent acquisitions by two of the largest pharmaceutical companies, it seems as if the historical orthodoxy tha...
09/16/2019

Based on recent acquisitions by two of the largest pharmaceutical companies, it seems as if the historical orthodoxy that great biopharma companies are made from the inside out may be losing validity. Download our whitepaper, Inside Out, written by Chris Ehrlich to join the discussion. http://bit.ly/insideoutwhitepaper

Inside Out: Do Recent Acquisitions by “Big Pharma” Sound the Alarm for the Traditional R&D Model? Based on recent acquisition activity by two of the largest pharmaceutical companies, it seems as if the historical orthodoxy that great biopharma companies are made from the inside out may be losing...

Our CEO and Co-Founder, Geoff Meyerson, just returned from a month in Europe as part of our effort to expand Locust Walk...
08/21/2019

Our CEO and Co-Founder, Geoff Meyerson, just returned from a month in Europe as part of our effort to expand Locust Walk European practice. It was a fantastic trip with valuable lessons. Click below to read.


http://bit.ly/EUVacation

Our medtech team took a deep dive into the Q2 data. Click below to download the report on latest trends and predictions ...
07/17/2019

Our medtech team took a deep dive into the Q2 data. Click below to download the report on latest trends and predictions for what's ahead.
http://bit.ly/Q2Medtech

As we close Q2, our global biopharma team has pulled the latest data with a keen eye on insights and trends. Click below...
07/17/2019

As we close Q2, our global biopharma team has pulled the latest data with a keen eye on insights and trends. Click below to download!
http://bit.ly/Q2Biopharma

Address

200 Clarendon Street 51st Floor
Boston, MA
02116

Opening Hours

Monday 8:30am - 5:30pm
Tuesday 8:30am - 5:30pm
Wednesday 8:30am - 5:30pm
Thursday 8:30am - 5:30pm
Friday 9am - 5:30pm

Telephone

+16173000161

Alerts

Be the first to know and let us send you an email when Locust Walk posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Locust Walk:

Share